X

Trial Profile

A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a (COVID-19 vaccine) in Japanese healthy adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DS 5670 (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Sponsors Daiichi Sankyo Company

Most Recent Events

14 Aug 2023 Status changed from recruiting to completed, as per results published in the Vaccine
14 Aug 2023 Results published in the Vaccine
17 Nov 2021 According to a Daiichi Sankyo Company media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com